EGFR+ Lung Cancer

>

Latest News

Amivantamab/Lazertinib Still Effective in EGFRm NSCLC Despite Dose Interruptions
Amivantamab/Lazertinib Still Effective in EGFRm NSCLC Despite Dose Interruptions

March 26th 2024

According to a subset analysis of the phase 3 MARIPOSA trial, dose interruptions during the course of amivantamab and lazertinib treatment were still effective in EGFR-mutant non-small cell lung cancer.

FDA Approves Amivantamab/Chemo in Advanced EGFR Exon20Ins Mut+ NSCLC
FDA Approves Amivantamab/Chemo in Advanced EGFR Exon20Ins Mut+ NSCLC

March 1st 2024

Osimertinib Enhances Progression-Free Survival in Stage III NSCLC
Osimertinib Enhances Progression-Free Survival in Stage III NSCLC

February 19th 2024

FDA Oks Osimertinib Plus Chemo in EGFR-Mutant Lung Cancer
FDA Oks Osimertinib Plus Chemo in EGFR-Mutant Lung Cancer

February 16th 2024

Worth The Wait? Genomic Testing Delays Initiation of Advanced NSCLC Therapy
Worth The Wait? Genomic Testing Delays Initiation of Advanced NSCLC Therapy

February 9th 2024

More News